Gibson RE, Burns HD, Hamill TG, et al. Ingentaconnect non-invasive radiotracer imaging as a tool for drug development[J]. Current Pharmaceutical Design, 2000, 6: 973-989.
[2]
Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer lymphoma and melanoma[J]. J Nuc Med, 1999, 40: 591-603.
[3]
Engel H, Steinert H, Buck A, et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations[J]. Nucl Med, 1996, 37: 441-446.
[4]
Varagnolo L, Stok kel MPM, Mazzi U, et al. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG[J]. Nuc Med Biol, 2000, 27: 103-112.
[5]
Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules[J]. J Clin Oncol, 1998, 16(3): 1 075-1 084.
Seiji Shinkai, Seiichi Mori, Hiroshi Koreishi, et al. Hexasulfonated Calix[6] larene derivatives: a new class of catalysts, surfactants, and host molecules[J]. J Am Chem Soc, 1986, 108: 2 409-2 416.
